Kalamazoo, Michigan, April 27, 2021 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) reported operating results for the first quarter of 2021:
The response to the COVID-19 pandemic has included measures to slow the spread of the virus taken by governments and health care authorities globally, including the postponement of elective medical procedures and social contact restrictions. While there is starting to be some recovery in certain geographies, there continues to be a negative impact on our operations and financial results.
First Quarter Results
- Reported net sales increased 10.2% from 2020 and 12.4% from 2019 to $4.0 billion
- Organic net sales increased 1.8% from 2020 and 4.7% from 2019
- Reported operating income margin of 11.6%
- Adjusted operating income margin(1) contracted 50 bps to 23.5%
- Reported EPS decreased 39.2% to $0.79
- Adjusted EPS(1) increased 4.9% to $1.93
In addition to sales growth analysis versus 2020, we are including sales growth versus 2019 as 2019 provides a more normal baseline for comparison given the variability caused by the COVID-19 pandemic throughout 2020.
“We are pleased with our results, as business picked up meaningfully in the latter part of the first quarter,” said Kevin Lobo, Chairman and Chief Executive Officer. “We expect this momentum to continue and are encouraged by the Wright Medical integration, which is pacing ahead of our expectations.”
Sales Analysis Compared to 2020 and 2019
Consolidated net sales of $4.0 billion increased 10.2% in the quarter and 8.0% in constant currency from 2020. Organic net sales increased 1.8% in the quarter including 2.7% from increased unit volume partially offset by 0.9% from lower prices. From 2019 consolidated net sales increased 12.4% in the quarter and 11.1% in constant currency. Organic net sales increased 4.7% in the quarter including 6.1% from increased unit volume partially offset by 1.4% from lower prices.
Orthopaedics net sales of $1.5 billion increased 21.4% in the quarter and 18.7% in constant currency from 2020. Organic net sales increased 0.5% in the quarter including 2.6% from increased unit volume partially offset by 2.1% from lower prices. From 2019 Orthopaedics net sales increased 18.7% in the quarter and 17.2% in constant currency. Organic net sales decreased 0.7% in the quarter including 2.7% from increased unit volume offset by 3.4% from lower prices.
MedSurg net sales of $1.6 billion remained flat in the quarter and decreased 1.6% in constant currency from 2020. Organic net sales decreased 1.6% in the quarter including 1.4% from decreased unit volume and 0.2% from lower prices. From 2019 MedSurg net sales increased 6.2% in the quarter and 5.3% in constant currency. Organic net sales increased 5.3% in the quarter from increased unit volume.
Neurotechnology and Spine net sales of $0.8 billion increased 14.0% in the quarter and 11.3% in constant currency from 2020. Organic net sales increased 11.3% in the quarter including 11.9% from increased unit volume partially offset by 0.6% from lower prices. From 2019 Neurotechnology and Spine net sales increased 14.6% in the quarter and 12.8% in constant currency. Organic net sales increased 12.8% in the quarter including 13.4% from increased unit volume partially offset by 0.6% from lower prices.
Earnings Analysis Compared to 2020
Reported net earnings of $302 million decreased 38.7% in the quarter. Reported net earnings per diluted share of $0.79 decreased 39.2% in the quarter. Reported gross profit margin and reported operating income margin were 63.5% and 11.6% in the quarter. Reported net earnings include certain items, such as charges for acquisition and integration-related activities, the amortization of purchased intangible assets, restructuring-related and other charges, costs to comply with certain medical device regulations, recall-related matters, regulatory and legal matters and tax matters. Excluding the aforementioned items, adjusted gross profit margin(1) was 65.4% in the quarter, and adjusted operating income margin(1) was 23.5% in the quarter, a decline of 50 basis points. Adjusted net earnings(1) of $737 million increased 5.4% in the quarter. Adjusted net earnings per diluted share(1) of $1.93 increased 4.9% in the quarter.
2021 Outlook
We continue to monitor and evaluate the impact the global response to the COVID-19 pandemic has had, and will continue to have, on our operations and financial results. As we recover from the pandemic, we continue to expect 2021 organic net sales growth to be in the range of 8% to 10% from 2019, as this is a more normal baseline given the variability throughout 2020, and now expect adjusted net earnings per diluted share(2) to be in the range of $9.05 to $9.30, including the full year impact of the acquisition of Wright Medical. Consistent with the pricing environment experienced in both 2019 and 2020, we expect continued unfavorable price reductions of approximately 1% in 2021. If foreign currency exchange rates hold near current levels, we expect EPS will be positively impacted by $0.05 to $0.10 for the full year. This guidance assumes an ongoing recovery in our key geographies leading to more normalized elective procedure levels during the second quarter of 2021. As previously announced, we will not be providing quarterly guidance.
(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.
(2) We are unable to present a quantitative reconciliation of our expected net earnings per diluted share to expected adjusted net earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of restructuring-related and other charges, acquisition-related expenses and fair value adjustments to inventory and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Earnings.
Conference Call on Tuesday, April 27, 2021
As previously announced, Stryker will host a conference call on Tuesday, April 27, 2021 at 4:30 p.m., Eastern Time, to discuss the company’s operating results for the quarter ended March 31, 2021 and provide an operational update.
To participate in the conference call dial (877) 702-4565 (domestic) or (647) 689-5532 (international) and be prepared to provide conference ID number 8988724 to the operator.
A simultaneous webcast of the call will be accessible via the company’s website at www.stryker.com. The call will be archived on the Investor Relations page of this site.
A recording of the call will also be available from 8:00 p.m., Eastern Time, on Tuesday, April 27, 2021, until 11:59 p.m., Eastern Time, on Tuesday, May 4, 2021. To hear this recording, you may dial (800) 585-8367 (domestic) or (416) 621-4642 (international) and enter conference ID number 8988724.
Caution Concerning Forward-Looking Statements
This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities laws that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: the impact on our operations and financial results of the COVID-19 pandemic and any related policies and actions by governments or other third parties; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright Medical Group N.V. (“Wright”); the effects of the Wright acquisition on the parties’ relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. Additional information concerning these and other factors is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The Company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.
For investor inquiries please contact:
Preston Wells, Vice President, Investor Relations at 269-385-2600 or [email protected]
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or [email protected]